Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin Plus Abiraterone in mCRPC
NCT07093866Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Nanjing Drum-Tower Hospital. Started Jul 2025; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07093866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07093866.